| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Not applicable; this is an isotopically labeled tracer. Unlabeled D-mannose is involved in protein glycosylation pathways, where it is activated to GDP-mannose and used for the synthesis of N-linked and O-linked glycoproteins. It also serves as a precursor for ascorbic acid synthesis in some species.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
D-Mannose-13C has the same biological activity as unlabeled mannose. Mannose is a key component of the glycosylation machinery in humans; deficiencies in mannose metabolism are associated with congenital disorders of glycosylation. The 13C label allows tracking of mannose carbon incorporation. |
| ln Vivo |
Not applicable; as a tracer, D-Mannose-13C is used to quantify mannose flux in glycosylation pathways. Unlabeled mannose has been shown to inhibit the growth of certain cancer cell lines by interfering with glucose metabolism and to reduce urinary tract infections by blocking bacterial adhesion.
|
| Enzyme Assay |
D-Mannose-13C (10-100 microM) is added to glycoprotein extracts or cell lysates. After de-glycosylation by PNGase F, released N-linked glycans are analyzed by LC-MS/MS to determine the 13C enrichment in mannose residues, providing information on glycan biosynthetic rates.
|
| Cell Assay |
HeLa, CHO, or other mammalian cells are cultured with D-Mannose-13C (1-20 mM) for 24-72 hours to metabolically label glycoproteins. Cells are lysed, and the 13C enrichment in GDP-mannose, dolichol-P-mannose, and mannose residues in N-linked glycans is measured by LC-MS/MS or NMR.
|
| Animal Protocol |
D-Mannose-13C (0.5-2 g/kg) is administered to mice or rats via intraperitoneal injection or oral gavage. Blood and tissues (liver, kidney, brain) are collected at 0.5, 1, 2, 4, 8, 24 hours. The 13C enrichment in plasma mannose, GDP-mannose, and glycoprotein mannose is quantified by LC-MS/MS.
|
| ADME/Pharmacokinetics |
Not available for D-Mannose-13C. Unlabeled D-mannose has an oral bioavailability of 30-50% in humans, with a plasma half-life of 2-4 hours. It is primarily excreted unchanged in urine (50-70% of absorbed dose) and is not significantly metabolized. The labeled version behaves identically.
|
| Toxicity/Toxicokinetics |
No toxicity; D-mannose is generally recognized as safe (GRAS) as a dietary supplement. It is well-tolerated at doses up to 10 g/day in humans. At very high doses (>1 g/kg in rodents), mild gastrointestinal disturbances (diarrhea, flatulence) may occur.
|
| References |
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
[2]. Genovese C, et al. Effects of a new combination of plant extracts plus d-mannose for the management of uncomplicated recurrent urinary tract infections. J Chemother. 2018 Apr;30(2):107-114. |
| Additional Infomation |
The 13C-labeled version is for research use only, not FDA-approved. Unlabeled D-mannose is available as a dietary supplement for the prevention of recurrent urinary tract infections. D-Mannose-13C is a valuable tool for studying metabolic disorders such as mannosidosis, congenital disorders of glycosylation, and cancer metabolism.
|
| Molecular Formula |
C513CH12O6
|
|---|---|
| Molecular Weight |
181.1485
|
| Exact Mass |
181.067
|
| CAS # |
70849-31-9
|
| Related CAS # |
D-Mannose;3458-28-4
|
| PubChem CID |
12285886
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.732g/cm3
|
| Melting Point |
133ºC(lit.)
|
| Index of Refraction |
1.635
|
| LogP |
-2.6
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
151
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C(C1C(C(C(C(O1)O)O)O)O)O
|
| InChi Key |
WQZGKKKJIJFFOK-YILIOCFTSA-N
|
| InChi Code |
InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5+,6?/m1/s1/i6+1
|
| Chemical Name |
(3S,4S,5S,6R)-6-(hydroxymethyl)(213C)oxane-2,3,4,5-tetrol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5203 mL | 27.6014 mL | 55.2029 mL | |
| 5 mM | 1.1041 mL | 5.5203 mL | 11.0406 mL | |
| 10 mM | 0.5520 mL | 2.7601 mL | 5.5203 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
